Cargando…

Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report

Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hao Xiang, Lin, Ching-Chan, Lin, Che-Hung, Yang, Chi-Rei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857427/
https://www.ncbi.nlm.nih.gov/pubmed/36661675
http://dx.doi.org/10.3390/curroncol30010026
_version_ 1784873866631315456
author Chen, Hao Xiang
Lin, Ching-Chan
Lin, Che-Hung
Yang, Chi-Rei
author_facet Chen, Hao Xiang
Lin, Ching-Chan
Lin, Che-Hung
Yang, Chi-Rei
author_sort Chen, Hao Xiang
collection PubMed
description Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting with anal bleeding and urethra obstruction who responded dramatically to combination therapy of durvalumab and cisplatin-based chemotherapy. The patient had HPV-positive penile squamous cell carcinoma, cT3N3M0, with concomitant anus squamous cell carcinoma. After 2 months of the combination treatment, almost all bulky inguinal lymph nodes shrank, and the main tumor of the anus and penis responded completely. A durable response was seen 16 months after initiating the combination therapy. This case report highlights the potential role of the combination of immunotherapy and chemotherapy in patients with advanced penile cancer. The promising results of this combination resulted in the conversion of unresectable disease to a potentially curable disease.
format Online
Article
Text
id pubmed-9857427
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98574272023-01-21 Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report Chen, Hao Xiang Lin, Ching-Chan Lin, Che-Hung Yang, Chi-Rei Curr Oncol Case Report Penile squamous cell carcinoma is a rare disease entity with poor overall survival in an advanced stage. Few studies have investigated the role of immunotherapy in advanced penile squamous cell carcinoma. Herein, we report a case of stage IV unresectable penile squamous cell carcinoma presenting with anal bleeding and urethra obstruction who responded dramatically to combination therapy of durvalumab and cisplatin-based chemotherapy. The patient had HPV-positive penile squamous cell carcinoma, cT3N3M0, with concomitant anus squamous cell carcinoma. After 2 months of the combination treatment, almost all bulky inguinal lymph nodes shrank, and the main tumor of the anus and penis responded completely. A durable response was seen 16 months after initiating the combination therapy. This case report highlights the potential role of the combination of immunotherapy and chemotherapy in patients with advanced penile cancer. The promising results of this combination resulted in the conversion of unresectable disease to a potentially curable disease. MDPI 2022-12-26 /pmc/articles/PMC9857427/ /pubmed/36661675 http://dx.doi.org/10.3390/curroncol30010026 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Chen, Hao Xiang
Lin, Ching-Chan
Lin, Che-Hung
Yang, Chi-Rei
Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title_full Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title_fullStr Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title_full_unstemmed Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title_short Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report
title_sort combination of durvalumab and chemotherapy to potentially convert unresectable stage iv penile squamous cell carcinoma to resectable disease: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857427/
https://www.ncbi.nlm.nih.gov/pubmed/36661675
http://dx.doi.org/10.3390/curroncol30010026
work_keys_str_mv AT chenhaoxiang combinationofdurvalumabandchemotherapytopotentiallyconvertunresectablestageivpenilesquamouscellcarcinomatoresectablediseaseacasereport
AT linchingchan combinationofdurvalumabandchemotherapytopotentiallyconvertunresectablestageivpenilesquamouscellcarcinomatoresectablediseaseacasereport
AT linchehung combinationofdurvalumabandchemotherapytopotentiallyconvertunresectablestageivpenilesquamouscellcarcinomatoresectablediseaseacasereport
AT yangchirei combinationofdurvalumabandchemotherapytopotentiallyconvertunresectablestageivpenilesquamouscellcarcinomatoresectablediseaseacasereport